[go: up one dir, main page]

LT3086637T - Gyvūnai, išskyrus žmogų, turintys humanizuota diferenciacijos klasterio 47 geną - Google Patents

Gyvūnai, išskyrus žmogų, turintys humanizuota diferenciacijos klasterio 47 geną

Info

Publication number
LT3086637T
LT3086637T LTEP15813960.0T LT15813960T LT3086637T LT 3086637 T LT3086637 T LT 3086637T LT 15813960 T LT15813960 T LT 15813960T LT 3086637 T LT3086637 T LT 3086637T
Authority
LT
Lithuania
Prior art keywords
differentiation
gene
human animals
humanized
cluster
Prior art date
Application number
LTEP15813960.0T
Other languages
English (en)
Inventor
Cagan Gurer
Ella Ioffe
Alexander MUJICA
Gavin Thurston
Original Assignee
Regeneron Pharmaceuticals, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=54979926&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=LT3086637(T) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Regeneron Pharmaceuticals, Inc. filed Critical Regeneron Pharmaceuticals, Inc.
Publication of LT3086637T publication Critical patent/LT3086637T/lt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • A01K67/0278—Knock-in vertebrates, e.g. humanised vertebrates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
    • A61K49/0008—Screening agents using (non-human) animal models or transgenic animal models or chimeric hosts, e.g. Alzheimer disease animal model, transgenic model for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4703—Inhibitors; Suppressors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70596—Molecules with a "CD"-designation not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5014—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing toxicity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5047—Cells of the immune system
    • G01N33/5055—Cells of the immune system involving macrophages
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5082—Supracellular entities, e.g. tissue, organisms
    • G01N33/5088—Supracellular entities, e.g. tissue, organisms of vertebrates
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2207/00—Modified animals
    • A01K2207/12—Animals modified by administration of exogenous cells
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2207/00—Modified animals
    • A01K2207/15—Humanized animals
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A01K2217/052—Animals comprising random inserted nucleic acids (transgenic) inducing gain of function
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/07—Animals genetically altered by homologous recombination
    • A01K2217/072—Animals genetically altered by homologous recombination maintaining or altering function, i.e. knock in
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/15—Animals comprising multiple alterations of the genome, by transgenesis or homologous recombination, e.g. obtained by cross-breeding
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/105—Murine
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A01K2267/0331—Animal model for proliferative diseases
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A01K2267/035—Animal model for multifactorial diseases
    • A01K2267/0381—Animal model for diseases of the hematopoietic system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70596—Molecules with a "CD"-designation not provided for elsewhere in G01N2333/705

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Urology & Nephrology (AREA)
  • Toxicology (AREA)
  • Genetics & Genomics (AREA)
  • Cell Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Hematology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Veterinary Medicine (AREA)
  • Environmental Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biodiversity & Conservation Biology (AREA)
  • Animal Husbandry (AREA)
  • Plant Pathology (AREA)
  • Public Health (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
LTEP15813960.0T 2014-12-05 2015-11-25 Gyvūnai, išskyrus žmogų, turintys humanizuota diferenciacijos klasterio 47 geną LT3086637T (lt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462087992P 2014-12-05 2014-12-05
PCT/US2015/062614 WO2016089692A1 (en) 2014-12-05 2015-11-25 Non-human animals having a humanized cluster of differentiation 47 gene

Publications (1)

Publication Number Publication Date
LT3086637T true LT3086637T (lt) 2019-04-10

Family

ID=54979926

Family Applications (3)

Application Number Title Priority Date Filing Date
LTEP18207075.5T LT3466255T (lt) 2014-12-05 2015-11-25 Gyvūnai, išskyrus žmogų, turintys humanizuotą diferenciacijos klasterio 47 geną
LTEP15813960.0T LT3086637T (lt) 2014-12-05 2015-11-25 Gyvūnai, išskyrus žmogų, turintys humanizuota diferenciacijos klasterio 47 geną
LTEP20215046.2T LT3850946T (lt) 2014-12-05 2015-11-25 Gyvūnai, išskyrus žmogų, turintys humanizuotą ląstelės diferenciacijos klasterio 47 geną

Family Applications Before (1)

Application Number Title Priority Date Filing Date
LTEP18207075.5T LT3466255T (lt) 2014-12-05 2015-11-25 Gyvūnai, išskyrus žmogų, turintys humanizuotą diferenciacijos klasterio 47 geną

Family Applications After (1)

Application Number Title Priority Date Filing Date
LTEP20215046.2T LT3850946T (lt) 2014-12-05 2015-11-25 Gyvūnai, išskyrus žmogų, turintys humanizuotą ląstelės diferenciacijos klasterio 47 geną

Country Status (29)

Country Link
US (5) US20160345549A1 (lt)
EP (4) EP3466255B1 (lt)
JP (2) JP6730277B2 (lt)
KR (3) KR102617691B1 (lt)
CN (2) CN107205368B (lt)
AR (1) AR102888A1 (lt)
AU (2) AU2015355328B2 (lt)
BR (1) BR112017010490A2 (lt)
CA (1) CA2967834C (lt)
CY (2) CY1121547T1 (lt)
DK (3) DK3086637T3 (lt)
ES (3) ES2716735T3 (lt)
FI (1) FI3850946T3 (lt)
HR (3) HRP20231707T1 (lt)
HU (3) HUE054661T2 (lt)
IL (2) IL286403B2 (lt)
LT (3) LT3466255T (lt)
MX (1) MX2017007293A (lt)
NZ (2) NZ769992A (lt)
PL (3) PL3466255T3 (lt)
PT (3) PT3466255T (lt)
RS (3) RS58536B1 (lt)
RU (1) RU2728412C2 (lt)
SG (2) SG11201703463WA (lt)
SI (3) SI3466255T1 (lt)
SM (3) SMT201900178T1 (lt)
TR (1) TR201903891T4 (lt)
TW (1) TWI681053B (lt)
WO (1) WO2016089692A1 (lt)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL3466255T3 (pl) 2014-12-05 2021-08-09 Regeneron Pharmaceuticals, Inc. Zwierzęta inne niż człowiek mające humanizowany gen kompleksu różnicowania 47
DK3230320T3 (da) 2014-12-09 2021-01-11 Regeneron Pharma Ikke_humane dyr med en humaniseret klynge af differentiering 274 gen
WO2016154299A1 (en) * 2015-03-24 2016-09-29 The Trustees Of Columbia University In The City Of New York Genetic modification of pigs for xenotransplantation
KR102377189B1 (ko) 2015-05-29 2022-03-22 리제너론 파마슈티칼스 인코포레이티드 C9orf72 유전자좌에서 파괴를 갖는 비-인간 동물
LT3376857T (lt) 2015-11-20 2021-06-25 Regeneron Pharmaceuticals, Inc. Gyvūnai, ne žmonės, turintys humanizuotą limfocitų aktyvavimo geną
KR102487839B1 (ko) 2016-02-04 2023-01-12 리제너론 파마슈티칼스 인코포레이티드 조작된 angptl8 유전자를 갖는 비인간 동물
RU2749715C2 (ru) 2016-02-29 2021-06-16 Регенерон Фармасьютикалз, Инк. Грызуны, характеризующиеся гуманизированным геном tmprss
JP7134944B2 (ja) * 2016-08-11 2022-09-12 ザ ジャクソン ラボラトリー 遺伝子改変免疫不全非ヒト動物における改良されたヒト赤血球生存に関連する方法および組成物
WO2018041119A1 (en) 2016-08-31 2018-03-08 Beijing Biocytogen Co., Ltd Genetically modified non-human animal with human or chimeric ox40
CN107815468B (zh) 2016-08-31 2021-03-16 百奥赛图(北京)医药科技股份有限公司 人源化基因改造动物模型的制备方法及应用
CN107815465B (zh) 2016-08-31 2021-03-16 百奥赛图(北京)医药科技股份有限公司 人源化基因改造动物模型的制备方法及应用
WO2018041121A1 (en) 2016-08-31 2018-03-08 Beijing Biocytogen Co., Ltd Genetically modified non-human animal with human or chimeric ctla-4
KR102527979B1 (ko) * 2016-09-30 2023-04-28 리제너론 파마슈티칼스 인코포레이티드 C9orf72 유전자좌에서 헥사뉴클레오티드 반복 확장을 갖는 비인간 동물
CN108467873B (zh) 2017-03-17 2020-03-13 百奥赛图江苏基因生物技术有限公司 一种cd132基因缺失的免疫缺陷动物模型的制备方法及应用
CN108588126B (zh) 2017-03-31 2020-04-10 北京百奥赛图基因生物技术有限公司 Cd47基因人源化改造动物模型的制备方法及应用
WO2018177441A1 (en) 2017-03-31 2018-10-04 Beijing Biocytogen Co., Ltd GENETICALLY MODIFIED NON-HUMAN ANIMAL WITH HUMAN OR CHIMERIC SIRPα
IL270835B2 (en) * 2017-06-12 2025-01-01 Sinai Health Sys Allograft tolerance without the need for systemic immunosuppression
NZ761568A (en) 2017-08-02 2022-11-25 Phanes Therapeutics Inc Anti-cd47 antibodies and uses thereof
EP4299732A3 (en) 2017-11-30 2024-03-27 Regeneron Pharmaceuticals, Inc. Rats comprising a humanized trkb locus
CA3093850A1 (en) * 2018-03-26 2019-10-03 Regeneron Pharmaceuticals, Inc. Humanized rodents for testing therapeutic agents
US11589562B2 (en) 2018-07-16 2023-02-28 Regeneran Pharmaceuticals, Inc. Mouse model of DITRA disease and uses thereof
US12331320B2 (en) 2018-10-10 2025-06-17 The Research Foundation For The State University Of New York Genome edited cancer cell vaccines
JP7449291B2 (ja) 2018-12-20 2024-03-13 リジェネロン・ファーマシューティカルズ・インコーポレイテッド ヌクレアーゼ媒介リピート伸長
WO2020147829A1 (zh) * 2019-01-17 2020-07-23 北京百奥赛图基因生物技术有限公司 人源化转基因动物
CN112430621B (zh) * 2019-08-09 2022-09-27 百奥赛图(北京)医药科技股份有限公司 Il2ra基因人源化的非人动物的构建方法及应用
CN112553252B (zh) * 2019-09-06 2022-04-29 百奥赛图(北京)医药科技股份有限公司 Tnfr2基因人源化的非人动物的构建方法和应用
CN113122574A (zh) * 2019-12-31 2021-07-16 百奥赛图(北京)医药科技股份有限公司 一种免疫缺陷型人源化非人动物的构建方法
CN112080522A (zh) * 2020-09-15 2020-12-15 广东药康生物科技有限公司 一种cd47人源化小鼠模型的构建方法
CN112725379B (zh) * 2021-01-27 2024-08-13 上海南方模式生物科技股份有限公司 人源化cd40基因改造动物模型的构建方法及应用
WO2023046061A1 (en) * 2021-09-24 2023-03-30 Biocytogen Pharmaceuticals (Beijing) Co., Ltd. Genetically modified non-human animal with human or chimeric trop2
AU2023310163A1 (en) 2022-07-19 2025-01-16 Regeneron Pharmaceuticals, Inc. Genetically modified animal model and its use to model the human immune system

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5670356A (en) 1994-12-12 1997-09-23 Promega Corporation Modified luciferase
US5874304A (en) 1996-01-18 1999-02-23 University Of Florida Research Foundation, Inc. Humanized green fluorescent protein genes and methods
US6586251B2 (en) 2000-10-31 2003-07-01 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
WO2005044857A1 (ja) * 2003-11-11 2005-05-19 Chugai Seiyaku Kabushiki Kaisha ヒト化抗cd47抗体
PL1802193T3 (pl) 2004-10-19 2014-09-30 Regeneron Pharma Sposób wytwarzania myszy homozygotycznej pod względem modyfikacji genetycznej
US20070113297A1 (en) 2005-09-13 2007-05-17 Yongguang Yang Methods and compositions for inhibition of immune responses
SG174053A1 (en) * 2006-09-01 2011-09-29 Therapeutic Human Polyclonals Inc Enhanced expression of human or humanized immunoglobulin in non-human transgenic animals
WO2009039244A2 (en) * 2007-09-18 2009-03-26 Genizon Biosciences Inc. Genemap of the human genes associated with crohn's disease
CN101668387A (zh) 2008-09-02 2010-03-10 鸿富锦精密工业（深圳）有限公司 印刷电路板
WO2010082385A1 (ja) * 2009-01-16 2010-07-22 財団法人実験動物中央研究所 ヒト肝細胞が移植されたマウス
RU2425880C2 (ru) * 2009-07-30 2011-08-10 Учреждение Российской академии наук Институт общей генетики им. Н.И. Вавилова РАН Способ получения трансгенных мышей
US8354389B2 (en) 2009-08-14 2013-01-15 Regeneron Pharmaceuticals, Inc. miRNA-regulated differentiation-dependent self-deleting cassette
WO2011034969A1 (en) * 2009-09-15 2011-03-24 The Board Of Trustees Of The Leland Stanford Junior University Synergistic anti-cd47 therapy for hematologic cancers
DK2485583T3 (en) 2009-10-06 2016-10-03 Regeneron Pharma GENETICALLY MODIFIED MICE AND inoculation
PT3375284T (pt) 2011-02-15 2023-06-28 Univ Yale Ratinhos humanizados para m-csf e utilizações dos mesmos
US20140242095A1 (en) * 2011-10-19 2014-08-28 University Health Network Antibodies and antibody fragments targeting sirp-alpha and their use in treating hematologic cancers
RS59997B1 (sr) 2011-10-28 2020-04-30 Regeneron Pharma Genetski modifikovani miševi sa ekspresijom himernih molekula klase ii glavnog kompleksa histokompatibilnosti (mhc)
MX358390B (es) 2011-10-28 2018-08-17 Regeneron Pharma Interleucina 6 y receptor de interleucina 6, humanizados.
SI2770821T1 (en) 2011-10-28 2018-01-31 Regeneron Pharmaceuticals, Inc. Genetically modified major histocompatibility complex of mice
EP2644027A1 (en) * 2012-03-26 2013-10-02 Institut Pasteur Transgenic immunodefficient mouse expressing human SIRPalpha.
US8962913B2 (en) 2012-06-18 2015-02-24 Regeneron Pharmaceuticals, Inc. Humanized IL-7 rodents
IL282472B2 (en) 2012-09-07 2024-04-01 Regeneron Pharma Genetically modified non-human animals and methods of their use
CN114766432B (zh) 2012-11-05 2024-08-02 再生元制药公司 经遗传修饰的非人动物及其使用方法
JP6572131B2 (ja) * 2012-12-12 2019-09-04 バスキュロックス インコーポレイテッド 治療用ｃｄ４７抗体
EP4374690A3 (en) 2013-02-20 2024-08-21 Regeneron Pharmaceuticals, Inc. Mice expressing humanized t-cell co-receptors
US20150342163A1 (en) 2013-02-22 2015-12-03 Regeneron Pharmaceuticals, Inc. Genetically modified major histocompatibility complex mice
KR102211267B1 (ko) 2013-02-22 2021-02-04 리제너론 파아마슈티컬스, 인크. 사람화된 주요 조직적합성 복합체를 발현하는 마우스
EP3434101B1 (en) 2013-09-23 2023-08-16 Regeneron Pharmaceuticals, Inc. Non-human animals having a humanized signal-regulatory protein gene
NZ718655A (en) 2013-10-15 2022-08-26 Regeneron Pharma Humanized il-15 animals
SG11201603360QA (en) 2013-11-19 2016-05-30 Regeneron Pharma Non-human animals having a humanized b-cell activating factor gene
WO2015077072A1 (en) 2013-11-19 2015-05-28 Regeneron Pharmaceuticals, Inc. Non-human animals having a humanized a proliferation-inducing ligand gene
AU2015243865C1 (en) 2014-04-08 2020-11-26 Regeneron Pharmaceuticals, Inc. Non-human animals having humanized Fc-gamma receptors
NO2785538T3 (lt) 2014-05-07 2018-08-04
ES2964597T3 (es) 2014-05-19 2024-04-08 Regeneron Pharma Ratones modificados genéticamente que expresan EPO humana
SG10201811116UA (en) 2014-06-19 2019-01-30 Regeneron Pharma Non-human animals having a humanized programmed cell death 1 gene
KR102659123B1 (ko) 2014-11-24 2024-04-22 리제너론 파마슈티칼스 인코포레이티드 인간화 cd3 복합체를 발현하는 비인간 동물
PL3466255T3 (pl) 2014-12-05 2021-08-09 Regeneron Pharmaceuticals, Inc. Zwierzęta inne niż człowiek mające humanizowany gen kompleksu różnicowania 47

Also Published As

Publication number Publication date
JP2018500012A (ja) 2018-01-11
JP7089554B2 (ja) 2022-06-22
US10015953B2 (en) 2018-07-10
EP3850946B1 (en) 2023-09-27
AU2015355328B2 (en) 2022-03-10
ES2716735T3 (es) 2019-06-14
AU2022203787A1 (en) 2022-06-23
EP4296278A2 (en) 2023-12-27
PL3086637T3 (pl) 2019-09-30
SG10202103050YA (en) 2021-05-28
JP2020168016A (ja) 2020-10-15
EP3086637A1 (en) 2016-11-02
KR20170098800A (ko) 2017-08-30
HUE064960T2 (hu) 2024-04-28
CN107205368B (zh) 2020-11-17
US11910788B2 (en) 2024-02-27
LT3466255T (lt) 2021-05-25
KR20230038599A (ko) 2023-03-20
TW201629210A (zh) 2016-08-16
AU2022203787B2 (en) 2025-01-30
US20160157470A1 (en) 2016-06-09
US20210161112A1 (en) 2021-06-03
HRP20210662T1 (hr) 2021-05-28
DK3850946T3 (da) 2024-01-08
CY1121547T1 (el) 2020-05-29
HRP20231707T1 (hr) 2024-03-15
PT3086637T (pt) 2019-03-26
EP3466255B1 (en) 2021-02-17
RS64989B1 (sr) 2024-01-31
RS58536B1 (sr) 2019-04-30
PL3466255T3 (pl) 2021-08-09
PL3850946T3 (pl) 2024-03-11
RU2728412C2 (ru) 2020-07-29
MX2017007293A (es) 2018-03-12
ES2870462T3 (es) 2021-10-27
EP4296278A3 (en) 2024-03-27
IL286403A (en) 2021-10-31
KR102313073B1 (ko) 2021-10-18
DK3850946T5 (da) 2024-08-19
PT3850946T (pt) 2024-01-02
AU2015355328A1 (en) 2017-05-18
IL286403B1 (en) 2023-06-01
PT3466255T (pt) 2021-05-10
TWI681053B (zh) 2020-01-01
DK3466255T3 (da) 2021-05-03
SMT202100281T1 (it) 2021-07-12
RU2017123357A (ru) 2019-01-09
KR102508175B1 (ko) 2023-03-09
EP3086637B1 (en) 2019-01-02
DK3086637T3 (en) 2019-04-08
HUE043132T2 (hu) 2019-07-29
SMT201900178T1 (it) 2019-05-10
CY1124089T1 (el) 2022-05-27
EP3850946A1 (en) 2021-07-21
SI3086637T1 (sl) 2019-04-30
WO2016089692A1 (en) 2016-06-09
HK1225912A1 (en) 2017-09-22
NZ731471A (en) 2021-12-24
SI3850946T1 (sl) 2024-02-29
LT3850946T (lt) 2024-01-10
JP6730277B2 (ja) 2020-07-29
CA2967834A1 (en) 2016-06-09
US20240138384A1 (en) 2024-05-02
IL252019A0 (en) 2017-06-29
SI3466255T1 (sl) 2021-07-30
US10939673B2 (en) 2021-03-09
KR102617691B1 (ko) 2023-12-27
IL252019B (en) 2021-10-31
US20180249689A1 (en) 2018-09-06
CN112342197B (zh) 2025-02-18
SMT202300482T1 (it) 2024-01-10
FI3850946T3 (fi) 2023-12-28
AR102888A1 (es) 2017-03-29
HRP20190634T1 (hr) 2019-08-09
RU2017123357A3 (lt) 2019-06-03
IL286403B2 (en) 2023-10-01
CN107205368A (zh) 2017-09-26
ES2969389T3 (es) 2024-05-17
KR20210127773A (ko) 2021-10-22
BR112017010490A2 (pt) 2018-04-03
HUE054661T2 (hu) 2021-09-28
CN112342197A (zh) 2021-02-09
NZ769992A (en) 2024-11-29
EP3466255A1 (en) 2019-04-10
RS61774B1 (sr) 2021-05-31
CA2967834C (en) 2024-01-16
TR201903891T4 (tr) 2019-04-22
US20160345549A1 (en) 2016-12-01
SG11201703463WA (en) 2017-05-30

Similar Documents

Publication Publication Date Title
IL282649A (en) Non-human animals with a humanized gene for differentiation cluster 274
IL286403A (en) Non-human animals having a humanized cluster of differentiation 47 gene
IL287519A (en) Non-human animals with a humanized programmed cell death gene 1
HK40108429A (en) Non-human animals having a humanized cluster of differentiation 274 gene
HK40096160A (en) Non-human animals having a humanized cluster of differentiation 47 gene